Ref. Ares(2020)2040853 - 14/04/2020
From:
@gsk.com>
Sent:
mardi 14 avril 2020 13:06
To:
BUCHER Anne (SANTE); SEYCHELL Martin (SANTE)
Cc:
@sanofi.com;
@sanofi.com;
@sanofi.com
Subject:
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight
COVID-19
Attachments:
Press Release - Sanofi and GSK to join forces in unprecedented vaccine
collaboration to fight COVID-19 14042020.pdf
Categories:
A voir par
Dear Mrs Bucher and Mr Seychell,
Today, Sanofi and GSK announce we are entering into a collaboration to develop an adjuvanted vaccine
for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic.
Definitive terms of the collaboration are expected to be finalised over the next few weeks.
Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology.
GSK will contribute its proven pandemic adjuvant technology to the collaboration. We plan to initiate
phase I clinical trials in the second half of 2020 and, if successful and subject to regulatory considerations,
aim to complete the development required for licensure
Considering the extraordinary humanitarian and financial challenge of the pandemic, both companies
believe that global access to COVID-19 vaccines is a priority and are committed to making any vaccine
that is developed through the collaboration affordable to the public and through mechanisms that offer fair
access for people in all countries.
It is clear no one company can address COVID-19 alone and we are proud that this collaboration brings
together two of the world’s largest vaccines companies.
The press release announcing this news is attached; please feel free to reach out if you have any
questions.
•
GSK:
@gsk.com
•
Sanofi Pasteur:
@sanofi.com
We have also informed President von der Leyen and Commissioners Kyriakides, Breton, Gabriel and
Lenarþiþ.
Best wishes,
Communications and Government Affairs, Vaccines
GSK
20, Avenue Fleming, Building W23, 1300 Wavre, Belgium
Email:
@gsk.com
Mobile:
Tel (landline):
gsk.com | Twitter | YouTube | Facebook | Flickr
GSK monitors email communications sent to and from GSK in order to protect GSK, our
employees, customers, suppliers and business partners, from cyber threats and loss of GSK
Information. GSK monitoring is conducted with appropriate confidentiality controls and in
accordance with local laws and after appropriate consultation.